Disease · MONDO_0003060
Comparisons in its trials34
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 34
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm A (Pembrolizumab+Gemcitabine+Cisplatin) vs Arm B (Placebo+Gemcitabine+Cisplatin): Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE) | 138 of 529 | 122 of 534 | 1,063 | NCT04003636 | Trial comparisons |
| Arm A (Pembrolizumab+Gemcitabine+Cisplatin) vs Arm B (Placebo+Gemcitabine+Cisplatin): Number of Participants Who Experience One or More Adverse Events (AE) | 524 of 529 | 532 of 534 | 1,063 | NCT04003636 | Trial comparisons |
| A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: deaths from any cause | 188 of 388 | 135 of 385 | 773 | NCT04163900 | Trial comparisons |
| A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: serious adverse events | 175 of 383 | 126 of 378 | 761 | NCT04163900 | Trial comparisons |
| Durvalumab + Gemcitabine + Cisplatin vs Placebo + Gemcitabine + Cisplatin: deaths from any cause | 308 of 341 | 326 of 344 | 685 | NCT03875235 | Trial comparisons |
| Durvalumab + Gemcitabine + Cisplatin vs Placebo + Gemcitabine + Cisplatin: serious adverse events | 168 of 338 | 152 of 342 | 680 | NCT03875235 | Trial comparisons |
| A - NUC-1031 and Cisplatin vs B - Gemcitabine and Cisplatin: Objective Response Rate (ORR) | 53 of 284 | 34 of 275 | 559 | NCT04163900 | Trial comparisons |
| Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond) vs Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond): deaths from any cause | 51 of 83 | 49 of 79 | 162 | NCT04677504 | Trial comparisons |
| Arm B: Atezo+PBO+CisGem (Cycle*1-8), Followed by Atezo+PBO (Cycle*9 and Beyond) vs Arm A: Atezo+Bev+CisGem (Cycle*1-8), Followed by Atezo+Bev (Cycle*9 and Beyond): serious adverse events | 43 of 81 | 36 of 78 | 159 | NCT04677504 | Trial comparisons |
| Pembrolizumab + Chemotherapy First Course vs Placebo + Chemotherapy First Course: deaths from any cause | 49 of 75 | 63 of 83 | 158 | NCT04924062 | Trial comparisons |
| Arm A (Pembrolizumab+Gemcitabine+Cisplatin) vs Arm B (Placebo+Gemcitabine+Cisplatin): Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE) | 18 of 74 | 14 of 82 | 156 | NCT04924062 | Trial comparisons |
| Arm A (Pembrolizumab+Gemcitabine+Cisplatin) vs Arm B (Placebo+Gemcitabine+Cisplatin): Number of Participants Who Experience One or More Adverse Events (AE) | 73 of 74 | 82 of 82 | 156 | NCT04924062 | Trial comparisons |
| Pembrolizumab + Chemotherapy First Course vs Placebo + Chemotherapy First Course: serious adverse events | 28 of 74 | 29 of 82 | 156 | NCT04924062 | Trial comparisons |
| Varlitinib and Capecitabine vs Placebo and Capecitabine: Number of Participants With Clinically Significant Laboratory Tests - Part 1 | 0 of 64 | 0 of 63 | 127 | NCT03093870 | Trial comparisons |
| Varlitinib and Capecitabine vs Placebo and Capecitabine: Number of Participants With Clinically Significant Change in Vital Signs and Physical Examinations - Part 1 | 0 of 64 | 0 of 63 | 127 | NCT03093870 | Trial comparisons |
8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine vs Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine: Number of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies | 3 of 74 | 0 of 37 | 111 | NCT02711553 | Trial comparisons |
| Gemcitabine + Sorafenib vs Gemcitabine + Placebo: serious adverse events | 33 of 49 | 35 of 48 | 97 | NCT00661830 | Trial comparisons |
| Cohort I vs Cohort II: ORR by Investigator Assessment | 34 of 80 | 0 of 7 | 87 | NCT04466891 | Trial comparisons |
| Cohort I vs Cohort II: Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR) | 33 of 80 | 0 of 7 | 87 | NCT04466891 | Trial comparisons |
| Cohort I vs Cohort II: DCR by Investigator Assessment | 54 of 80 | 1 of 7 | 87 | NCT04466891 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0003060/comparisons